Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About 300,000 shares were transacted today in the last 30 minutes at prices that rose steadily from $.154 to $.165. This amounts to about $50,000. I infer that some positive news has leaked from the Company. A new buyer has stepped up as I believe long-term shareholders have been tapped out for some time.
A time will come (more than a year from now) when potential acquirers will look at the U.S. market which is ten times the Canadian market and price a buyout according to the U.S. market.
I recall once seeing a gross profit estimate (after costs of production) to MZEI of $45,000 per unit and a selling price estimate of $90,000 per unit. With the sales you suggest of 50 units per year this would produce revenue of $2,250,000 per year. Would this not cover their other costs leaving them at break even?
Or it could be that people who have bought shares at well below market prices in private placements are unloading those shares at market prices for an excellent gain. How many more such shares are on the sidelines waiting for sale?
I do not understand your post. Would you please explain? Possibly you are calling attention to what you believe to be a purchase at a favorable price.
High volume at about 380,000 shares today. About half of the transactions were at roughly $.075 per share in the earlier part of the day; about half of the transactions were at roughly $.085 per share in the later part of the day.
Whenever I am sad or lonely I go to iHUB to read the latest posts on MZEI. The amusement they give seldom fails to pick up my spirits. Based on very limited knowledge I have the impression of EM being like a boxer who has been pummeled for 13 rounds and is staggering off his stool for the 14th convinced that he will prevail. I am not sure I learn much from the iHUB posts but they certainly do amuse me.
Are you trying to put SandPenny and me into a bidding war with each other?
186,000 shares @ $.10 per share is $18,6000. If powerpak, shoexx and judypudy can rustle up that much money it could power MZEI through the "overhead resistance" to untold heights. Since you are so optimistic about the Company's prospects, why not do it?
For a huge jump in price new buyers must come along. Will new buyers even know about MZEI?
Yes. Another $20,000 purchase.
It would appear that a speculator (there are no investors in Medizone) paid $20,000 for 190,000 shares and a market maker sold the shares to him/her from inventory.
Perhaps one of the cheerleaders took a second mortgage on their home and bought on a tip from Ed Marshall!
After reviewing the market makers bids and offers at Level 2 I infer the following. If someone wanted to sell 100,000 shares of MZEI the prices they would receive would in part be as low as $.07. If someone wanted to buy 100,000 shares of MZEI the prices they would pay would in part be as high as $.12.
Are you mymetizone or mymedizone? Is there an important difference?
Rather than mouth off on this message board, why not contact members of the BOD who I believe have responsibility for the governance of the Company. Are Directors not responsible for removing a CEO who is not capable?
There was a 200 share transaction at $.1079 at the end of the day.
91,800 shares were SOLD to a market maker at $.10.
Why don't you and BenK stop guessing about what the science guys have been doing and what their intentions and outlook are. Talk to them and get their take on the management and their outlook on MZEI.
10Q: As of October 2012, Medizone had a total of 15 full-time employees and consultants.
Since Medizone has limited resources (money and personnel) perhaps this patent could be sold off for immediate cash and a future revenue stream.
On a commercial basis, the 3 log kill rate you describe seems satisfactory to the hospital in question.
I just saw a video on Yahoo news of a "germ blasting robot" at Baptist Easley Hospital. They hope to get more units. At $125,000 they consider it to be cost effective. The hospital spokesperson said it kills 99.9% of bacteria/germs. It appears to use UV light.
It is the last week of summer---brokerage desks are manned by less experienced personnel.
I repeat my post #25088 of 6-18-12.
"I suspect the reason the major shareholder group has not acted forcefully is that they feel their hands are tied. Shannon is tied to Marshall at the hip and it is feared that he would leave if Ed's authority is curtailed. Shannon's superb medical talents are not matched by business savvy."
Thank you. Your post is extremely reassuring.
Many companies are selling at relative lows. The market is risk averse. Investors are barely paying for fundamentals, let alone any upside story.
We could not turn out machines fast enough for them. This would put them under pressure to reverse engineer and turn out large number of machines without benefit to MZEI.
I suspect the reason the major shareholder group has not acted forcefully is that they feel their hands are tied. Shannon is tied to Marshall at the hip and it is feared that he would leave if Ed's authority is curtailed. Shannon's superb medical talents are not matched by business savvy.
Powerpak---You should try to be more optimistic!
Antibiotic Resistance Could Bring 'End of Modern Medicine'
By Katie Moisse | ABC News Blogs
As bacteria evolve to evade antibiotics, common infections could become deadly, according to Dr. Margaret Chan, director general of the World Health Organization.
Speaking at a conference in Copenhagen, Chan said antibiotic resistance could bring about "the end of modern medicine as we know it."
"We are losing our first-line antimicrobials," she said Wednesday in her keynote address at the conference on combating antimicrobial resistance. "Replacement treatments are more costly, more toxic, need much longer durations of treatment, and may require treatment in intensive care units."
Chan said hospitals have become "hotbeds for highly-resistant pathogens" like methicillin-resistant Staphylococcus aureus, "increasing the risk that hospitalization kills instead of cures."
Indeed, diseases that were once curable, such as tuberculosis, are becoming harder and more expensive to treat.
Chan said treatment of multidrug resistant tuberculosis was "extremely complicated, typically requiring two years of medication with toxic and expensive medicines, some of which are in constant short supply. Even with the best of care, only slightly more than 50 percent of these patients will be cured."
Antibiotic-resistant strains of salmonella, E. coli, and gonorrhea have also been discovered.
"Some experts say we are moving back to the pre-antibiotic era. No. This will be a post-antibiotic era. In terms of new replacement antibiotics, the pipeline is virtually dry," said Chan. "A post-antibiotic era means, in effect, an end to modern medicine as we know it. Things as common as strep throat or a child's scratched knee could once again kill."
The dearth of effective antibiotics could also make surgical procedures and certain cancer treatments risky or even impossible, Chan said.
"Some sophisticated interventions, like hip replacements, organ transplants, cancer chemotherapy and care of preterm infants, would become far more difficult or even too dangerous to undertake," she said.
The development of new antibiotics now could help stave off catastrophe later. But few drug makers are willing to invest in drugs designed for short term use.
"It's simply not profitable for them," said Dr. William Schaffner, chairman of preventive medicine at Vanderbilt University Medical Center in Nashville. "If you create a new drug to red cholesterol, people will be taking that drug every day for the rest of their lives. But you only take antibiotics for a week or maybe 10 days."
Schaffner likened the dilemma to Ford releasing a car that could only be driven if every other vehicle wasn't working.
"While we try to encourage the pharmaceutical industry to create new antibiotics, we have to be very prudent in their use," he said.
But there are ways to limit the potential for bacteria to develop antibiotic resistance: Use antibiotics appropriately and only when needed; follow treatment correctly; and restrict the use of antibiotics in food production to therapeutic purposes.
"At a time of multiple calamities in the world, we cannot allow the loss of essential antimicrobials, essential cures for many millions of people, to become the next global crisis," said Chan.
WIV: Without disagreeing with the points in your post I would like to add two more points for thought.
(1) If a portion of the Company is sold off how would the continuing R&D efforts be handled? They cannot be readily split.
(2) There would be dissension over accepting an offer within each of the groups---major shareholder group; miscellaneous shareholders; management/directors. "Tired longs" would be pitted against those who wish to hold out for further anticipated gains.
It is crystal ball gazing.
I believe that there is a 50% chance that near the end of this year MZEI will get an unsolicited offer to acquire certain commercial applications of our business such as bedbugs, cruise ships, locker rooms, etc. for, say, $2.00 per share. I have no idea how management/large shareholders would react to such an offer. If the U.S. patent is in hand, and product performance is successful, this may goose F500's to step up their interest in MZEI. Such interest might take the form of buying an option for acquisition of MZEI at certain prices on certain dates.
I have an optimistic view of MZEI’s outlook. The Chairman’s Message II gave a conservative base case showing the Company is on very sound ground. Had Ed given conservative “state of the Company” reports in the past he would not have taken so much flak. By using conservative financials he shows he has learned not to over promise.
Using what I regard as more realistic assumptions I expect the following six/eight months from now: Successful completion of hotel/motel testing (and orders totaling over 100 units); hospital testing; terrorism testing (in Canada); and other applications possibly including food processing. U.S. and/or international base patents issued. An expanded management team with recognizable credentials. Same unit can be used in different applications (with different protocols). Necessary certifications developed for product-entry to various countries.
Even a small number of distributors will not be satisfied with a mere forty units sold this year.
By six/eight months I believe one or more F500 Companies will be forced to make a move to take over MZEI. To wait would give more time for development of alternative
technologies, reverse engineering, and outright copying by Chinese outfits. I anticipate a tax-free share swap.
TEB, Doberman, Phrantic, Waterdog, etc. are catching their breath for stretch runs, to be followed by victory laps!
I believe today's market action was due to buyers who waited until they thought tax loss selling was over. I suspect BOD's Soloman's SEC filing was the final catalyst in convincing them that MZEI was not only a buy, but a screaming buy.
It sounds as though you may be a great contrary indicator!
Link to the abstract for the Peer Reviewed Article on AcepticSure:
http://www.ajicjournal.org/article/S0196-6553(11)00160-X/abstract?elsca1=etoc&elsca2=email&elsca3=%0d%0a%200196-
6553_201112_39_10&elsca4=elsevier
Hard Copy of Peer Reviewed Article Issued:
American Journal of Infection Control: December 2011 (Volume 39, Issue 10)
Post #22167 gave excerpts from the 10Q. I was impressed at the progress the Company has made. Have you seen this post?